Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients

References

• Kris MG, Natale RB, Herbst RS, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer. JAMA 2003;290:2149-58
   PubMed Web of Science ®Google Scholar
• Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol 2008;26:2350-7
   PubMed Web of Science ®Google Scholar
• Fukuoka M, Yano S, Giaccone G, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J Clin Oncol 2003;21:2237-46
   PubMed Web of Science ®Google Scholar
• Liu L, Li W, Li L, et al. Iressa for the non-small cell lung cancer patients who failed prior chemotherapy and radiotherapy. Zhongguo Fei Ai Za Zhi 2004;7:321-4
   PubMedGoogle Scholar
• Mu XL, Li LY, Zhang XT, et al. Evaluation of safety and efficacy of gefitinib ('iressa', zd 1839) as monotherapy in a series of Chinese patients with advanced non-small-cell lung cancer: experience from a compassionate-use programme. BMC Cancer 2004;4:51
   PubMed Web of Science ®Google Scholar
• Guan ZZ, Zhang L, Li LY, et al. Efficacy of gefitinib on Chinese patients with locally advanced or metastatic non-small cell lung cancer: a clinical trial. Ai Zheng 2005;24:980-4
   PubMedGoogle Scholar
• Zhang XT, Li LY, Mu XL, et al. The EGFR mutation and its correlation with response of gefitinib in previously treated Chinese patients with advanced non-small-cell lung cancer. Ann Oncol 2005;16:1334-42
   PubMed Web of Science ®Google Scholar
• Chang GC, Tsai CM, Chen KC, et al. Predictive factors of gefitinib antitumor activity in East Asian advanced non-small cell lung cancer patients. J Thorac Oncol 2006;1:520-5
   PubMed Web of Science ®Google Scholar
• Yang L, Liu X, Fang J, et al. Gefitinib in the treatment of advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 2006;28:474-7
   PubMedGoogle Scholar
• Wang MZ, Li LY, Wang SL, et al. Efficacy and safety of gefitinib as monotherapy for Chinese patients with advanced non-small cell lung cancer. Chin Med J (Engl) 2006;119:63-8
   PubMed Web of Science ®Google Scholar
• Xu JM, Han Y, Li YM, et al. Phase II trial of sequential gefitinib after minor response or partial response to chemotherapy in Chinese patients with advanced non-small-cell lung cancer. BMC Cancer 2006;6:288
   PubMed Web of Science ®Google Scholar
• Zhang L, Yu SY. Gefitinib in the treatment of advanced non-small-cell lung cancer. Zhonghua Zhong Liu Za Zhi 2006;28:539-54
   PubMedGoogle Scholar
• Zheng H, Wang J, Meng Q, et al. Target therapy of gefitinib in advanced adenocarcinoma of the lung. Zhongguo Fei Ai Za Zhi 2007;10:229-33
   PubMedGoogle Scholar
• Lin L, Zhang L, Zhao H, et al. Predictive factors of gefitinib response and survival in Chinese patients with local advanced or metastatic non-small cell lung cancer. Zhongguo Fei Ai Za Zhi 2007;10:411-17
   PubMedGoogle Scholar
• Zhang L, Wang SL, Zhang XT, et al. Efficacy and safety of gefitinib monotherapy for Chinese elderly patients with advanced non-small cell lung cancer. Zhonghua Nei Ke Za Zhi 2007;46:392-5
   PubMedGoogle Scholar
• Wang Y, Zhang X, Wang B, et al. Clinic outcome of gefitinib in sixty-nine elderly patients with lung adenocarcinoma. Zhongguo Fei Ai Za Zhi 2008;11:137-41
   PubMedGoogle Scholar
• Kang M, Yang Z, Liu Y, et al. Evaluation of efficacy of gefitinib on advanced non-small-cell lung cancer (NSCLC) resisted to chemotherapy. Zhongguo Fei Ai Za Zhi 2008;11:292-3
   PubMedGoogle Scholar
• Zhong W, Wang MZ, Zhang L, et al. Evaluation of efficacy and safety of gefitinib as monotherapy in Chinese patients with advanced non-small cell lung cancer and very poor performance status. BMC Res Notes 2008;1:102
   PubMedGoogle Scholar
• Zhao Y, Zhang Y, Zhao H, et al. Predictive factors for response and survival of gefitinib-treated locally advanced or metastatic non-small cell lung cancer patients: a retrospective analysis of two phase II clinical trials. Ai Zheng 2009;28:626-31
   PubMedGoogle Scholar
• Lu Y, Wang ZJ, An TT, et al. A phase II trial of gefitinib as maintenance therapy after first-line chemotherapy for advanced non-small cell lung cancer in China. Chin J Cancer Res 2010;22:1-9
   Web of Science ®Google Scholar
• Dai L, Fang J, Nie J, et al. Analysis of Prognostic Factors of 80 advanced NSCLC patients treated with gefitinib for more than 6 months. Zhongguo Fei Ai Za Zhi 2010;13:1050-5
   PubMedGoogle Scholar
• Guo J, Zhou SW, Zhang L, et al. Prediction of epidermal growth factor receptor mutations in the plasma/pleural effusion to efficacy of gefitinib treatment in advanced non-small cell lung cancer. J Cancer Res Clin 2010;136:1341-7
   PubMed Web of Science ®Google Scholar
• Yin YM, Geng YT, Shao YF, et al. First-line single agent treatment with gefitinib in patients with advanced non-small-cell lung cancer. J Exp Clin Cancer Res 2010;29:126
   PubMedGoogle Scholar
• Deng J, Fang WJ, Zhang XC, et al. Phase II trial of gefitinib in pretreated Chinese women with advanced non-small-cell lung cancer. Med Oncol 2011;29:595-9
   PubMed Web of Science ®Google Scholar
• Chang GC, Chen KC, Yang TY, et al. Activity of gefitinib in advanced non-small-cell lung cancer with very poor performance status. Invest New Drugs 2005;23:73-7
   PubMed Web of Science ®Google Scholar
• Cataldo VD, Gibbons DL, Pérez-Soler R, et al. Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med 2011;364:947-55
   PubMed Web of Science ®Google Scholar
• Ciuleanu T, Brodowicz T, Zielinski C, et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study. Lancet 2009;374:1432-40
   PubMed Web of Science ®Google Scholar
• Hida T, Okamoto I, Kashii T, et al. Randomized phase III study of platinum-doublet chemotherapy followed by gefitinib versus continued platinum-doublet chemotherapy in patients (pts) with advanced non-small cell lung cancer (NSCLC): results of West Japan Thoracic Oncology Group trial (WJTOG). J Clin Oncol 2008;26:427s
   Google Scholar
• Lee DH, Park K, Kim JH, et al. Randomized phase III trial of gefitinib versus docetaxel in non-small cell lung cancer patients who have previously received platinum-based chemotherapy. Clin Cancer Res 2010;16:1307-14
   PubMed Web of Science ®Google Scholar
• Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010;362:2380-8
   PubMed Web of Science ®Google Scholar
• Kim ES, Hirsh V, Mok T, et al. Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial. Lancet 2008;372:1809-18
   PubMed Web of Science ®Google Scholar
• Forsythe B, Faulkner K. Overview of the tolerability of gefitinib (IRESSA) monotherapy: clinical experience in non-small-cell lung cancer. Drug Saf 2003;27:1081-92
   Web of Science ®Google Scholar
• Cappuzzo F, Hirsch FR, Rossi E, et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 2005;97:643-55
   PubMed Web of Science ®Google Scholar
• Han SW, Kim TY, Hwang PG, et al. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 2005;23:2493-501
   PubMed Web of Science ®Google Scholar
• Tokumo M, Toyooka S, Kiura K, et al. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin Cancer Res 2005;11:1167-73
   PubMed Web of Science ®Google Scholar
• Pao W, Wang TY, Riely GJ, et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005;2:e17
   PubMed Web of Science ®Google Scholar